Daejeon, South Korea

Minsik Song

This inventor holds 1 USPTO granted patent. Top assignee: The Catholic University of Korea. Active years: 2021.


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Minsik Song: Innovator in Genetic Detection Technologies

Introduction

Minsik Song is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of genetic detection, particularly in the diagnosis of myeloproliferative neoplasms. His innovative work has the potential to enhance the accuracy and efficiency of genetic testing.

Latest Patents

Minsik Song holds a patent for a "Peptide nucleic acid probe for multiplex detection of BCR/ABL negative myeloproliferative neoplasm-associated gene mutations." This invention provides a peptide nucleic acid probe that includes specific nucleic acid sequences designed to bind to genes associated with BCR/ABL negative myeloproliferative neoplasms. The technology enables rapid and accurate multiplex detection of gene mutations, which is crucial for effective diagnosis, follow-up, prognosis estimation, and treatment of related diseases.

Career Highlights

Minsik Song is affiliated with The Catholic University of Korea, where he continues to advance research in genetic technologies. His work is characterized by a commitment to improving diagnostic methods and patient outcomes in the field of oncology.

Collaborations

Minsik has collaborated with notable colleagues, including Yonggoo Kim and Myungshin Kim. Their joint efforts contribute to the ongoing development of innovative solutions in genetic research.

Conclusion

Minsik Song's contributions to genetic detection technologies exemplify the impact of innovation in healthcare. His work not only enhances diagnostic capabilities but also paves the way for improved patient care.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…